利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

150 条记录 (耗时 0.062 秒)

    Genetic modification of C57 mice
    25.
    发明授权
    Genetic modification of C57 mice 失效
    C57小鼠的遗传修饰

    公开(公告)号：US07132282B2

    公开(公告)日：2006-11-07

    申请号：US10768350

    申请日：2004-01-30

    申请人： Wei He ,  Wei Weng

    发明人： Wei He ,  Wei Weng

    IPC分类号： C12N5/00 ,  C12N5/02 ,  C12N5/06 ,  C12N5/10 ,  C12N15/00

    CPC分类号： A01K67/0275 ,  A01K2227/105 ,  C12N15/873 ,  C12N2517/10

    摘要： The present invention relates generally to the field of generating genetically modified C57 mice. More particularly, the present invention pertains to 1) blastocyst-derived mouse embryonic stem cell (ES) cell lines including, but not limited to, the IC1, IC2, IAC1, IAC2, IAC3, IAC4, IAC5, IAC6, IAC7 or IAC8 ES cell line, 2) to efficient methods of making genetically modified C57 mice by introducing the modified C57 ES cells into the mouse blastocysts of either the same mouse strain and/or color of albino C57 strain, or other C57 strain, to generate genetically modified novel, useful and hereto unknown models of C57 mice, and to methods for identifying the chimerism of chimeras which can be not known by coat color.

    摘要翻译： 本发明一般涉及生产转基因C57小鼠的领域。 更具体地说，本发明涉及1）囊胚来源的小鼠胚胎干细胞（ES）细胞系，包括但不限于IC1，IC2，IAC1，IAC2，IAC3，IAC4，IAC5，IAC6，IAC7或IAC8 ES 细胞系，2）通过将修饰的C57ES细胞引入与白化C57株或其他C57菌株相同的小鼠品系和/或颜色的小鼠胚泡中来生产经遗传修饰的C57小鼠的有效方法，以产生转基因小鼠 ，有用的和未知的C57小鼠模型，以及用于鉴定嵌合体的嵌合体的方法，其可以不被外壳颜色所知。

    Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
    26.
    发明申请
    Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists 审中-公开
    氮杂桥连双环氨基酸衍生物作为α4整联蛋白拮抗剂

    公开(公告)号：US20060223846A1

    公开(公告)日：2006-10-05

    申请号：US11370665

    申请日：2006-03-08

    申请人： Alexey Dyatkin ,  Yong Gong ,  Wei He ,  Tamara Miskowski

    发明人： Alexey Dyatkin ,  Yong Gong ,  Wei He ,  Tamara Miskowski

    IPC分类号： C07D453/02 ,  A61K31/46

    CPC分类号： C07D453/02 ,  C07D453/06

    摘要： The invention is directed to aza-bridged-bicyclic compounds having Formula (I): and pharmaceutically acceptable salts thereof. The compounds are useful α4 integrin receptor antagonists and, in particular, α4β1 and α4β7 integrin receptor antagonists. The invention is further directed to methods for use of the instant compounds for treating integrin mediated disorders including, but not limited to, inflammatory disorders, autoimmune disorders and cell-proliferative disorders, methods for preparing the compounds and methods for preparing the intermediates, derivatives and pharmaceutical compositions thereof.

    摘要翻译： 本发明涉及具有式（I）的氮杂桥联双环化合物及其药学上可接受的盐。 该化合物是有用的α4整联蛋白受体拮抗剂，特别是α4β1和α4β7整联蛋白受体拮抗剂。 本发明进一步涉及本发明化合物用于治疗整联蛋白介导的病症的方法，包括但不限于炎症性疾病，自身免疫性疾病和细胞增殖性疾病，制备化合物的方法和制备中间体，衍生物和 其药物组合物。

    Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
    30.
    发明申请
    Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists 审中-公开
    氮杂桥连双环氨基酸衍生物作为α4整联蛋白拮抗剂

    公开(公告)号：US20050176755A1

    公开(公告)日：2005-08-11

    申请号：US10976091

    申请日：2004-10-27

    申请人： Alexey Dyatkin ,  Yong Gong ,  Tamara Miskowski ,  Wei He

    发明人： Alexey Dyatkin ,  Yong Gong ,  Tamara Miskowski ,  Wei He

    IPC分类号： C07D451/14 ,  C07D453/06 ,  C07D453/04 ,  A61K31/407 ,  A61K31/46

    CPC分类号： C07D453/06

    摘要： The invention is directed to aza-bridged-bicyclic compounds having Formula (I): and pharmaceutically acceptable salts thereof. The compounds are useful α4 integrin receptor antagonists and, in particular, α4β1 and α4β7 integrin receptor antagonists. The invention is further directed to methods for use of the instant compounds for treating integrin mediated disorders including, but not limited to, inflammatory disorders, autoimmune disorders and cell-proliferative disorders, methods for preparing the compounds and methods for preparing the intermediates, derivatives and pharmaceutical compositions thereof.

    摘要翻译： 本发明涉及具有式（I）的氮杂桥联双环化合物及其药学上可接受的盐。 该化合物是有用的α4整联蛋白受体拮抗剂，特别是α4β1和α4β7整联蛋白受体拮抗剂。 本发明进一步涉及本发明化合物用于治疗整联蛋白介导的病症的方法，包括但不限于炎症性疾病，自身免疫性疾病和细胞增殖性疾病，制备化合物的方法和制备中间体，衍生物和 其药物组合物。